0
0
6/24/23 at 12:56am
Organization
Medscape
42 words
0
Comments
Weekly tirzepatide injections in adults with type 2 diabetes and overweight or obesity safely produced a 12.8%-14.7% weight loss after 72 weeks in the SURMOUNT-2 pivotal trial.
You are the first to view
https://www.medscape.com/viewarticle/993660
Create an account
or login to join the discussion